EP3654997A1 - Extrait aqueux d'un broyat de planaires - Google Patents
Extrait aqueux d'un broyat de planairesInfo
- Publication number
- EP3654997A1 EP3654997A1 EP18731890.2A EP18731890A EP3654997A1 EP 3654997 A1 EP3654997 A1 EP 3654997A1 EP 18731890 A EP18731890 A EP 18731890A EP 3654997 A1 EP3654997 A1 EP 3654997A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- aqueous extract
- organisms
- aqueous
- cells
- ground material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006286 aqueous extract Substances 0.000 title claims abstract description 50
- 239000000463 material Substances 0.000 title claims description 19
- 241000397921 Turbellaria Species 0.000 title description 14
- 210000004027 cell Anatomy 0.000 claims abstract description 35
- 241000282414 Homo sapiens Species 0.000 claims abstract description 24
- 210000005260 human cell Anatomy 0.000 claims abstract description 14
- 230000008929 regeneration Effects 0.000 claims abstract description 13
- 238000011069 regeneration method Methods 0.000 claims abstract description 13
- 210000004102 animal cell Anatomy 0.000 claims abstract description 10
- 239000007787 solid Substances 0.000 claims abstract description 6
- 230000003834 intracellular effect Effects 0.000 claims abstract description 5
- 239000013592 cell lysate Substances 0.000 claims abstract description 4
- 210000000130 stem cell Anatomy 0.000 claims description 18
- 238000001228 spectrum Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 241000242594 Platyhelminthes Species 0.000 claims description 8
- 239000006143 cell culture medium Substances 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 7
- 230000003071 parasitic effect Effects 0.000 claims description 7
- 241000282412 Homo Species 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 230000001172 regenerating effect Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 238000004949 mass spectrometry Methods 0.000 claims description 5
- 230000003712 anti-aging effect Effects 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 241001331901 Mediterranea Species 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 41
- 230000012010 growth Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 235000003276 Apios tuberosa Nutrition 0.000 description 4
- 244000105624 Arachis hypogaea Species 0.000 description 4
- 235000010777 Arachis hypogaea Nutrition 0.000 description 4
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000242531 Dugesia japonica Species 0.000 description 4
- 241001325293 Schmidtea mediterranea Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000935985 Certhiidae Species 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 241000366197 Paludicola Species 0.000 description 1
- 241001414536 Planaria torva Species 0.000 description 1
- 241001533308 Polycelis nigra Species 0.000 description 1
- 241000556207 Schmidtea Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920006113 non-polar polymer Polymers 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- -1 phopholipids Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/82—Undefined extracts from animals from invertebrates
Definitions
- Aqueous extract of a mash of planarians Aqueous extract of a mash of planarians.
- the present invention relates to a preparation based on extract of platyhelminth organisms useful especially for the regeneration of mammalian human or animal cells.
- planar is used to refer to a number of flatworms of the Plathelminths Branch. It mainly refers to non-exclusively parasitic freshwater Turbeilaridae, the Paludicola, but is also used for marine Turbeliaridae, diverer for all flatworms.
- Plathelminths are flatworms, many of which are parasites.
- This branch mainly includes worms that are elongated animals without appendices.
- the best known worms of the class Turbellaria flatworms not exclusively parasitic
- Planarians are therefore aquatic flatworms belonging to several species in the class Turbeilaridae. Planarians can be swimmers or creepers, and live in the sea or in fresh water, or in very humid soils (in tropical forest).
- Planarians are organisms capable of perpetual regeneration, and any part of the body, because of the presence of a large amount of stem cells (20-30%) in its tissues compared to other living organisms for which the amount of stem cells is of the order of lppm.
- the planar stem cells multiply and regenerate continuously, unlike the stem cells of more advanced organisms, which do not multiply or little. Biochemical factors allowing the multiplication of stem cells in a planarian remain unidentified.
- WO 99/33479 describes therapeutic use for the treatment of autoimmune diseases of cercarial preparations, pathogenic parasites which naturally colonize humans and do not exhibit the property of regeneration, the preparations being obtained by recovering parasite eggs from hamster liver injected with said cercarial organisms.
- an aqueous extract of planarian flatworms, non-parasitic and non-pathogenic in humans or animals, especially of the species Schmidtea mediterranea is capable of activating propagation.
- human stem cells, which planar extract because of this cell regeneration activity can therefore be useful in many cosmetic or medical applications, including dermatological, or food.
- non-parasitic and non-pathogenic in humans or animals is understood to mean that said organisms do not colonize humans or mammalian animals, whether through ingestion or through the skin, actively or passively, by altering pathologically, human cells or tissues or mammalian animals.
- the present invention provides a useful aqueous extract in particular for the regeneration of mammalian human or animal cells, comprising an aqueous extract freed from any solid insoluble debris of mash of platyhelmint-like organisms having regenerative capacity, said organisms being non-parasitic and non-pathogenic planar-type waterworms in man or mammalian animal, said aqueous extract containing at least the intracellular components of cells of said organisms of a cell lysate of said cells of said whole organisms.
- cellular state is meant here that the cells of said organisms are mechanically broken so that the intracellular components are released in said extract during the grinding of said organism, and said aqueous extract of ground is an aqueous extract of said crushed organisms. freed from any solid non-soluble debris, that is to say that one thus retains somehow that the "planar juice” resulting from the mechanical grinding containing only the intracellular components of the cells of said organisms of a cell lysate said cells of said organisms, but all components and not just peptides and proteins.
- non-parasitic and non-pathogenic planar aquatic flatworms in humans include Schmidtea mediterranea, Dugesia japonica, Dendricoelum lacteum, Polycelis nigra, Polycelys held / Planaria torva.
- said aqueous extract of ground material comprises a supernatant centrifugation said ground.
- said aqueous extract of ground material further comprises a cell culture medium, preferably a culture medium capable of cultivating human or animal cells to be regenerated.
- said aqueous extract of ground material comprises the ground material of 50 to 200 mg of whey / ml of aqueous solution, in particular for worms of 1 to 5 mg, said aqueous extract of ground material being further diluted preferably to more than l / 5th and less than 1 / lOOdoor, preferably diluted to l / 10th to l / 50th; including l / 2U th, preferably diluted in said cells of said culture medium.
- the said aqueous extract of ground material comprises the ground material of 88 to 110 mg of whey / ml of aqueous solution, that is to say 40 to 50 to / ml, the said aqueous extract of ground material being in further diluted to 1 / 20th.
- a spectrum of said extract of an aqueous millet by MALDI TOF type mass spectrometry comprises the 16 characteristic peaks (ie greater intensities (maximum S / N value) mentioned in Table 1 below. , wherein the different characteristic peaks are numbered in the first column, and the following parameters have the following meanings:
- the present invention also provides a lyophilizate of an aqueous extract of groundnut according to the invention.
- the present invention also provides a process for producing an aqueous extract of groundnut according to the invention characterized in that the steps are carried out in which: a) said living organisms, preferably which have been washed with water and have not not fed for at least one week, are placed in an aqueous liquid medium preferably containing a cell culture medium; b) the aqueous preparation obtained in step a) is milled, in particular by mechanical grinding, until the cells of said organisms are lysed, preferably the crushed material being between 5 and 10 ⁇ m in size (ie debris smaller than the size of cells of the said organisms); c) the insoluble debris is removed by centrifugation; and the supernatant is recovered, d) preferably, the centrifugation supernatant is diluted in an aqueous solution to more than 1/5 th and less than 1 / 100th, preferably diluted between 1 /
- the present invention also relates to the use of an aqueous extract of ground or lyophilizate according to the invention for the manufacture of a composition useful for regenerating mammalian human or animal cells, especially stem or differentiated cells.
- differentiated cells of the following types are mentioned: epithelial, fibroblast, keratinocyte, endothelial, neuronal or nervous.
- the present invention also relates to the use of an aqueous extract of ground or lyophilizate according to the invention for the manufacture of a composition useful for regenerating mammalian human or animal stem cells, for example a composition useful for regenerating cells.
- a composition useful for regenerating mammalian human or animal stem cells for example a composition useful for regenerating cells.
- the present invention also relates to the use of an aqueous extract of ground or lyophilizate according to the invention for the manufacture of a cosmetic or dermatological composition in combination with suitable carriers and / or excipients, in particular a cosmetic or dermatological composition anti-aging formulated for a topical application in the form of a gel, lotion (in particular an aqueous solution or serum), cream, ointment, soap and paste (especially for a mask).
- suitable carriers and / or excipients in particular a cosmetic or dermatological composition anti-aging formulated for a topical application in the form of a gel, lotion (in particular an aqueous solution or serum), cream, ointment, soap and paste (especially for a mask).
- the present invention also relates to the use of an aqueous extract of ground or lyophilizate according to the invention for the manufacture of a food composition. More particularly, an anti-aging cosmetic product according to the invention is formulated for topical application in the form of a gel, lotion, cream, ointment, soap or paste.
- the topical compositions according to the invention may comprise various conventional excipients suitable for external topical administration, in particular dermatologically and cosmetologically acceptable excipients.
- excipients suitable for formulation are well known to those skilled in the art and include, for example, penetration enhancers, moisturizers, thickeners, emollients and surfactants, emulsifiers; preservatives.
- Topical administration are prepared by the known techniques, and for example, in the case of a cream, by dispersion of a fatty phase in an aqueous phase to obtain an oil-in-water emulsion, or conversely to prepare a water-in-oil emulsion.
- the cosmetic product according to the invention is formulated in the form of a cream comprising, said aqueous extract and at least the following additional excipients: emulsifying agent, emollient agent, thickening agent, moisturizing agent and preserving agent and adjusting agent from Ph.
- the cosmetic product according to the invention is formulated in the form of an aqueous solution (in particular saline water serum) or an aqueous gel comprising, as a homogeneous mixture in water, said aqueous extract and for the gel at least the following additional excipients of age! gelling agent, thickening agent, moisturizing agent and preserving agent and ph adjusting agent.
- aqueous solution in particular saline water serum
- aqueous gel comprising, as a homogeneous mixture in water, said aqueous extract and for the gel at least the following additional excipients of age! gelling agent, thickening agent, moisturizing agent and preserving agent and ph adjusting agent.
- the preparations generally contain other excipients and / or auxiliaries and sometimes other active ingredients, for example dyes, coloring pigments, radical scavengers, perfumes, stabilizing agents.
- Cosmetics can also include auxiliaries and sometimes others active ingredients, for example antioxidant vitamins such as vitamin E, vitamin C, antioxidants such as natural polyphenols, enzymes, plant active ingredients, natural anti-inflammatory substances, alcohols, polyols, esters, electrolytes, polar oils and nonpolar polymers, copolymers, phopholipids, dyes; perfumes; or skin scrubbing agents.
- antioxidant vitamins such as vitamin E, vitamin C
- antioxidants such as natural polyphenols, enzymes, plant active ingredients, natural anti-inflammatory substances, alcohols, polyols, esters, electrolytes, polar oils and nonpolar polymers, copolymers, phopholipids, dyes; perfumes; or skin scrubbing agents.
- the invention also relates to a cosmetic process for treating 'skin to fight against the signs of skin aging, in particular wrinkles caused by facial muscle twitches, comprising applying to areas of the skin requiring such treatment, a topical cosmetic product according to the invention.
- the subject of the present invention is therefore a cosmetic composition with an anti-aging effect on its skin comprising an aqueous or lyophilized extract according to the invention and suitable excipients for topical application in the form of a gel, lotion, cream, ointment or soap.
- Figures 1A and 1C show growth at day 9 terTie human dental stem cells treated with extracts of planar Example 3A diluted l / 20 th ( Figure 1A; aqueous extract (Al), extract containing! PBS (A2) and extracts containing cell culture medium (A3) diluted l / 5th (figurelB) and l / 100th ( Figure 1C).
- FIG. 2 represents microphotographs showing its growth of human stem cells treated with extract A diurned at 1/20 for 9 days (B2) and before treatment (B1). The cells are stained Giemsa.
- FIG. 3 represents the absence of growth at the 9 th day of the human cells treated with whole planar groyne which has not been freed from the solid debris of Example 1.
- FIG. 4 represents the growth of the human cells treated with the solubilized lyophilized extract of Example 3B.
- Planar trees of the species Schmidtea mediterranea are maintained at 19 ° C in sterile filtered water on activated carbon / ceramic cartridge and 0.22 ⁇ m millipore filter membrane, without antibiotics. The water is changed every two to three days to eliminate waste such as planar droppings. Planarians are fed calf liver once a week. They are deprived of food 1 week before the experiments to purge them. Their average weight is 2.2mg / worm.
- Human dental pulp stem cells are maintained under standard in vitro culture conditions in cell culture medium DMEM / F12 (GibCoBRL) supplemented with fetal calf serum (10%) and antibiotic compounds such as than penicillin and streptomycin. (5000 U / mS, 5000 ⁇ g / ml respectively), at a temperature of 37 ° C under a 5% CO 2 atmosphere. The cells are resolved once a week, after trypsinization (0.05%) to detach the adherent cells, by a 1/3 dilution in DMEM / F12 culture medium (GibCoBRL) supplemented with fetal calf serum (10).
- DMEM / F12 GibCoBRL
- fetal calf serum fetal calf serum
- PBS buffer Phosphate Buffer Salts, IX
- the planaires are ground with a plastic pestle, and then the extract is passed 10 times (round trip) through a syringe 23G, to break the cells, the debris mill being between 5 and 10 pm. lb) The extract is then centrifuged at 200 g for 5 minutes, at a temperature of
- the centrifuged extract then has 2 phases, a dense phase at the bottom of the tube and a supernatant aqueous phase.
- the supernatant aqueous phase is then removed (around 500 ⁇ 1) and stored frozen at -80 ° C, or frozen in liquid nitrogen (-196 ° C), as an de ⁇ aliquot before use.
- An aqueous extract of planar broth centrifugation supernatant containing frozen culture medium is prepared according to Protocol A above, is placed in a 2 ml glass vial for lyophilization with cap placed at a temperature of -20 ° C. C overnight before lyophilization.
- the freeze-drying is carried out in a COSMOS lyophilizer of the company CRYOTEC (France) for one night.
- the lyophilisate is then stored at + 4 ° C in the dark until use. Before use, the lyophilisate is resuspended in 500 ⁇ l of sterile distilled water.
- Example 3A Incubation of human stem cells with the aqueous extract obtained according to protocol A.
- Supernatants for centrifugation of the planar broyast of the S. mediterranea species obtained in step 1b) of Example 1 are added to different final dilutions of 1/5, 1/8 and 1/100 th to stem cells.
- the cells are then maintained under the following conditions: 37 ° C, 5% CO 2 atmosphere for 9 days. After 9 days the cells are listed and the growth determined.
- FIGS. 1A to 1C show the growth of the human stem cells treated with extracts A1 to A3 diluted 1: 5 (FIG. 1A), the extract A3 (with culture medium) at 1: 20 (FIG. 1B), and the extract A3 (with culture medium) to 1 / 100th ( Figure 1C), for 9 days. (* P ⁇ 0.05). On the ordinate, the relative multiplication ratio of the cells with respect to a control without a groundnut extract was quantified.
- FIG. 2 shows the growth of human stem cells treated with extract A containing culture medium (A3) diluted 1/20 for 9 days (A2) and control before treatment (Al). The cells are stained Giemsa.
- a maximal increase is observed with more than 40% increase in the number of cells in the presence of aqueous extracts with water alone (Al) and containing PBS (A2) diluted to 1 / 20th compared to control culture without extract according to the invention.
- Example 3B Incubation of human stem cells with lyophilized planar extract (according to Sequence B):
- the lyophilizate (B) is resuspended in 500 ⁇ l of water and then added to a final dilution of 1/20 to human dental stem cells at a rate of 5 ⁇ 10 3 cells / well, 48-well plate, cultured in culture.
- DMEM / F12 medium GibCoBRL
- penicillin and streptomycin 5000U / ml, 5000Mg / ml respectively
- the cells are then maintained under the following conditions: 37 ° C, 5% CO 2 atmosphere for 9 days.
- FIG. 4 the growth of human stem cells treated with extract B diluted 1/20 for 9 days is shown. (* P ⁇ 0.05) On the ordinate, the relative multiplication ratio of the cells was quantified with respect to a control without a groundnut extract
- Example 4 maldi-tof type mass spectrum of the planar extract.
- mass spectrometry is a physical analysis technique for detecting and identifying molecules of interest by measuring their mass. Its principle lies in the gas phase separation of charged molecules (ions) according to their mass / charge ratio (m / z). The applications of mass spectrometry are very large and mainly concern the identification of peptides or proteins, the analysis of their amino acid sequence or the demonstration of post-translational modifications.
- Mass spectrometry under its MALDI-TOF variant has become essential in recent years in biology laboratories. Indeed, its assets are numerous: (1) speed of identification (in minutes); (2) precision of identification (without the need to know the type of microorganism sought); and (3) low cost per sample (less than 50 cents per sample),
- Example 3A An aqueous extract sample to water alone Al diluted to l / 20th of Example 3A was loaded onto a HCCA matrix, the trichioracITA acid, water, and acetonitrile. The analysis is performed on a Maldi-Tof Microflex LT10 mass spectrometer. The results are collected with MALDI Biotyper RTC software. One pL of supernatant is deposited on the target plate of the spectrometer and then dried for 10 minutes. One ⁇ of saturated HCCA matrix solution is added over, dried for 10 minutes, and then a mass spectrum of the protein extract is made on a Microflex TM LT (Bruker).
- the spectral acquisition method includes the following steps and features:
- IS1 electrode 20.00 kV
- IS2 electrode 18.05 kV
- Focusing electrode 6 kV
- Laser frequency 60Hz
- Detector gain 8.8 X
- Post-ion-extraction 120 ns
- Mass range from 700 to 20000 Da.
- the spectra are obtained via an automatic method controlled by the software FLEXCONTROL® of the manufacturer BRUKER DALTONICS® the parameters are the following for each spot:
- the acquisition of the spectra is ultimately carried out via the BIOTYPER® software of the manufacturer BRUKER DALTONICS® which makes it possible to apply the automatic method described above to a series of samples taking into account the criteria mentioned above and a quality score. or validation score which represent the addition of 2 notes ni + n2 (and being a function of the number of peaks and n2 function of the signal / background noise ratio):
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Pediatric Medicine (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1756929A FR3069163B1 (fr) | 2017-07-21 | 2017-07-21 | Extrait aqueux d'un broyat de planaires |
| PCT/FR2018/051246 WO2019016436A1 (fr) | 2017-07-21 | 2018-05-30 | Extrait aqueux d'un broyat de planaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3654997A1 true EP3654997A1 (fr) | 2020-05-27 |
Family
ID=60080986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP18731890.2A Withdrawn EP3654997A1 (fr) | 2017-07-21 | 2018-05-30 | Extrait aqueux d'un broyat de planaires |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210161973A1 (fr) |
| EP (1) | EP3654997A1 (fr) |
| FR (1) | FR3069163B1 (fr) |
| WO (1) | WO2019016436A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4376836A1 (fr) * | 2021-07-30 | 2024-06-05 | Oncomedics | Compositions et procédés de décontamination et de culture d'un échantillon de tractus gastro-intestinal |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69221686T2 (de) * | 1991-03-01 | 1998-04-02 | Atherton Investments Ltd | Therapeutische und kosmetische zusammensetzungen zur hautbehandlung |
| EP1749534B1 (fr) * | 1997-12-31 | 2013-08-21 | University Of Iowa Research Foundation | Utilisation d'agent biologiques parasitaires permettant de prévenir et de lutter contre les maladies intestinales inflammatoires |
-
2017
- 2017-07-21 FR FR1756929A patent/FR3069163B1/fr not_active Expired - Fee Related
-
2018
- 2018-05-30 WO PCT/FR2018/051246 patent/WO2019016436A1/fr not_active Ceased
- 2018-05-30 EP EP18731890.2A patent/EP3654997A1/fr not_active Withdrawn
- 2018-05-30 US US16/632,652 patent/US20210161973A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210161973A1 (en) | 2021-06-03 |
| WO2019016436A1 (fr) | 2019-01-24 |
| FR3069163A1 (fr) | 2019-01-25 |
| FR3069163B1 (fr) | 2020-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7563463B2 (en) | Cosmetic slimming composition containing an extract of biomass of the alga Neochloris oleoabundans | |
| EP2911680B1 (fr) | Utilisation d'un extrait de lin provenant de l'hydrolyse des protéines de lin, en tant qu'agent actif antimicrobien | |
| WO2010119191A1 (fr) | Composition cosmétique et/ou pharmaceutique comprenant un hydrolysat peptidique capable de renforcer la fonction barrière | |
| EP2182964A2 (fr) | Utlisation d'un principe actif issu du lin dans une composition destinee a activer le cytochrome c | |
| EP3280497A1 (fr) | Extrait hydro-alcoolique de schinus molle, compositions cosmetiques le comprenant et leurs utilisations cosmetiques | |
| EP3370833A1 (fr) | Extrait synergique depalmaria palmata | |
| FR3004349A1 (fr) | Applications cosmetiques et pharmaceutiques de lactobacillus pentosus | |
| KR102098871B1 (ko) | 역미셀을 형성하는 발효유화제를 이용한 안티인플라메이징 조성물 | |
| EP2763652A2 (fr) | Utilisation de glucanes obtenus a partir de prunus persica comme agent cosmetique anti-age | |
| EP3654997A1 (fr) | Extrait aqueux d'un broyat de planaires | |
| EP2958547B1 (fr) | Utilisation cosmétique de la queuine | |
| KR102935552B1 (ko) | 역미셀을 형성하는 발효유화제를 이용한 항노화 조성물 | |
| FR2953725A1 (fr) | Procede pour obtenir un extrait standardise de quercetine et de 3-o-methylquercetine a partir d'inflorescences de macela-do-campo, et composition cosmetique, pharmaceutique et veterinaire le contenant | |
| FR3104416A1 (fr) | Extraits de bourgeons de roses | |
| WO2024126964A1 (fr) | Composition cosmetique comprenant un extrait de levure metschnikowia rubicola | |
| JP2024506893A (ja) | ブラジルナッツノキ抽出物及びその使用 | |
| WO2008145850A2 (fr) | Utlisation d'un principe actif issu de l'amarante (amaranthus hypochondriacus) pour preparer une composition destinee a proteger les mitochondries | |
| FR2926461A1 (fr) | Nouveau facteur de croissance cellulaire d'origine non animale et applications | |
| FR3105259A1 (fr) | Cellules végétales dédifférenciées non élicitées deLavandula angustifolia, ses extraits et ses utilisations cosmétiques | |
| US20230310513A1 (en) | Method for feeding a flatworm and flatworm extract free of human-pathogenic microorganisms | |
| WO2014029948A2 (fr) | Extrait de lin et composition cosmetique comprenant ledit extrait pour augmenter le niveau de coenzyme q10 intracellulaire | |
| KR101320045B1 (ko) | 박테리오클로로필 함유 균체 파쇄물을 유효성분으로 포함하는 화장료 조성물 | |
| WO2008145848A2 (fr) | Composition pharmaceutique et/ou cosmetique contenant des peptides derives de l ' aconitase | |
| JP2003335696A (ja) | 水溶性キトサンと木香抽出物で構成された天然セル伝達体 | |
| FR3151198A1 (fr) | Nouvelles utilisations dermatologiques d’un extrait de la microalgue Dunaliella tertiolecta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200113 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20210430 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20230225 |